[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638668":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":144,"collaborators":11,"id":146,"slug":147,"hasResults":148,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":11,"eligibilityCriteria":152,"healthyVolunteers":148,"sex":153,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":11,"studyType":159,"phases":160,"briefSummary":162,"conditions":163,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},{"fullName":5,"class":6},"Ausper Biopharma Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"AHB-171 in Treatment CHB","EXPERIMENTAL",null,[13],"Drug: AHB-171 Injection",{"label":15,"type":10,"description":11,"interventionNames":16},"AHB-171 in Naïve CHB",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","AHB-171 Injection","Subcutaneous injection",[15,9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Bella Lu","CONTACT","0571-86959519","clinicaltrial@ausperbio.com",[30,46,57,68,79,90,101,112,122,133],{"facility":31,"status":32,"city":33,"state":34,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"AusperBio Investigational Site","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44,45],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"facility":31,"status":32,"city":47,"state":48,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Chongqing","Chongqing Municipality",{"type":38,"coordinates":50},[51,52],106.55771,29.56026,{"lat":52,"lon":51},[55,56],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"facility":31,"status":32,"city":58,"state":59,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Xiamen","Fujian",{"type":38,"coordinates":61},[62,63],118.08187,24.47979,{"lat":63,"lon":62},[66,67],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"facility":31,"status":32,"city":69,"state":70,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Guangzhou","Guangdong",{"type":38,"coordinates":72},[73,74],113.25,23.11667,{"lat":74,"lon":73},[77,78],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"facility":31,"status":32,"city":80,"state":81,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Nanning","Guangxi",{"type":38,"coordinates":83},[84,85],108.31667,22.81667,{"lat":85,"lon":84},[88,89],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"facility":31,"status":32,"city":91,"state":92,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Zhengzhou","Henan",{"type":38,"coordinates":94},[95,96],113.64861,34.75778,{"lat":96,"lon":95},[99,100],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"facility":31,"status":32,"city":102,"state":103,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Changzhou","Jiangsu",{"type":38,"coordinates":105},[106,107],119.95401,31.77359,{"lat":107,"lon":106},[110,111],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"facility":31,"status":32,"city":113,"state":114,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Jilin City","Jilin",{"type":38,"coordinates":116},[117,118],126.5608,43.84652,{"lat":118,"lon":117},[121],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"facility":31,"status":32,"city":123,"state":124,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Chengdu","Sichuang",{"type":38,"coordinates":126},[127,128],104.06667,30.66667,{"lat":128,"lon":127},[131,132],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"facility":31,"status":32,"city":134,"state":135,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Hangzhou","Zhejiang",{"type":38,"coordinates":137},[138,139],120.16142,30.29365,{"lat":139,"lon":138},[142,143],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"type":145,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100638668","phase-2-study-of-ahb-171-in-chronic-hepatitis-b-participants-100638668",false,"NCT07630727","Study of AHB-171 in Chronic Hepatitis B Participants","An Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of AHB-171 Injection in Participants With Chronic Hepatitis B","Inclusion Criteria:\n\n* Able to fully understand and sign the informed consent form (ICF).\n* Male or female participants, aged 18-65 years (inclusive).\n* Body mass index (BMI) meeting the predefined eligibility range.\n* Chronic hepatitis B (CHB) participants with HBsAg or HBV DNA positivity for ≥6 months at screening.\n* At screening, participants meeting predefined ranges of HBsAg, HBV DNA, and ALT according to prior nucleos(t)ide analogue (NA) treatment history (stable prior treatment or treatment-naive), and meeting corresponding prior antiviral treatment duration requirements.\n* Adopt effective contraceptive measures as required\n\nExclusion Criteria:\n\n* History of any severe systemic disease or malignancy other than chronic HBV infection which, in the opinion of the investigator, makes the subject unsuitable for study participation.\n* Prior history of solid organ or hematopoietic stem cell transplantation.\n* History of any other liver disease that the investigator considers unsuitable for trial.History of autoimmune disease or diseases with potential immune activation risk.\n* History or presence of hepatic decompensation at screening.\n* History of primary liver cancer, or diagnosis\u002Fsuspected liver cancer at screening.\n* Imaging or histological evidence of significant liver fibrosis or cirrhosis within 12 months prior to screening, or a liver stiffness measurement indicative of significant fibrosis or cirrhosis at screening. Major trauma or major surgery within 12 weeks prior to screening\n* History of severe allergies (e.g., to ≥2 allergens) or severe allergy to any component of the study drug, or in the opinion of the investigator, makes the subject unsuitable for participation.\n* Severe infection requiring intravenous anti-infective therapy within 2 weeks prior to screening (excluding chronic HBV infection).\n* History of drug abuse, or alcoholism.\n* Blood donation or blood loss exceeding the specified volume within 12 weeks prior to screening, or planned blood donation during the trial period.\n* Use of immunosuppressants, immunomodulators, cytotoxic drugs, or biologics within 6 months prior to screening.\n* Use of any oligonucleotide drugs or interferon therapy within 12 months prior to screening.\n* Vaccination within 4 weeks prior to screening, or planned vaccination during the trial period.\n* Presence of tattoos, active skin diseases, or other conditions that may interfere with subcutaneous drug administration or observation of injection site reactions.\n* Clinically significant abnormal electrocardiogram (ECG) at screening.\n* Tested positive for HIV，HCV or active syphilis infection.\n* Uncontrolled hypertension at screening.\n* Clinically significant abnormal laboratory test as specified in protocol at screening.\n* Currently participating in another clinical trials, or within the washout period.\n* Any other condition or factor which, in the opinion of the investigator, makes the subject unsuitable for trial participation.","ALL","18 Years","65 Years",{"count":157,"type":158},138,"ESTIMATED","INTERVENTIONAL",[161],"PHASE2","The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative\u002Fpositive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)",[164],"Hepatitis B, Chronic (CHB)","2026-07-20",{"date":167,"type":168},"2026-07-21","ACTUAL",{"date":170,"type":168},"2026-06-24",{"date":172,"type":158},"2029-05-31",{"name":5,"class":6},10]